Mirati Therapeutics, Inc.
MRTXNASDAQHealthcare
$58.70
$-0.10(-0.17%)
Market Cap$4.1B
P/E Ratio—
52W High$64.41
52W Low$27.3
Mirati Therapeutics, Inc. (MRTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MRTX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $12.44M | $72.09M | $13.40M | $3.33M | $12.93M |
| Cost of Revenue | $0.60M | $1.78M | $299.35M | $182.87M | $93.87M |
| Gross Profit | $11.84M | ($436.50M) | ($285.95M) | ($179.53M) | ($80.95M) |
| Gross Margin %(computed) | 95.18% | -605.48% | — | — | -626.23% |
| Operating Expenses | |||||
| R&D Expenses | $531.63M | $508.59M | $299.35M | $182.87M | $93.87M |
| G&A Expenses | $0.00M | $136.68M | $83.41M | $42.57M | $21.68M |
| Total Operating Expenses | $771.42M | $645.27M | $382.76M | $33.73M | $115.55M |
| Operating Income | ($759.59M) | ($573.18M) | ($369.36M) | ($222.10M) | ($102.63M) |
| Operating Margin %(computed) | — | -795.07% | — | — | -793.96% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($740.36M) | ($578.49M) | ($357.94M) | ($213.26M) | ($98.42M) |
| Income Tax Expense | $0.51M | $3.30M | ($0.51M) | ($0.66M) | $0.00M |
| Net Income | ($740.87M) | ($581.78M) | ($357.94M) | ($213.26M) | ($98.42M) |
| Net Margin %(computed) | — | -807.00% | — | — | -761.40% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-13.18 | $-11.21 | $-7.96 | $-5.69 | $-3.19 |
| Wtd Avg Shares | 56.23M | 51.88M | 44.99M | 37.47M | 30.90M |
| EBITDA | ($756.66M) | ($571.40M) | ($368.72M) | ($221.85M) | ($102.63M) |
| EBITDA Margin %(computed) | — | -792.60% | — | — | -793.96% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Mirati Therapeutics, Inc. data
About Mirati Therapeutics, Inc. (MRTX) Income Statement
Mirati Therapeutics, Inc. (MRTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, MRTX reported revenue of $0.01B, gross profit of $0.01B (gross margin 95.18%), and net income of ($0.74B) — a net profit margin of -5957.44%.
Frequently asked questions
MRTX · 4 questionsMirati Therapeutics, Inc. (MRTX) reported revenue of $0.01B for 2022, down 82.7% year-over-year.
MRTX revenueMRTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09